UNSPSC 51111659: Topotecan

This classification denotes a camptothecin analogue, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7M7YKX2N15. European Medicines Agency schedules Topotecan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11191MIG. Topotecan generally arises in the molecular formula C23H23N3O5. The term TOPOTECAN is an International Non-Proprietary Name or INN. TOPOTECAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule topotecan under HS 29399900 and SITC 54149. As of Q4 2014, TOPOTECAN remains the US FDA Preferred Term for this commodity. Topotecan bears US NLM identifiers UMLS ID C0146224 and NCI Concept Code C1413. SMILES: O1CC2C(C(O)(CC)C1=O)CC1N(CC3C1NC1C(C3)C(CN(C)C)C(O)CC1)C2=O.

UNSPSC 51111659 Topotecan, a Commodity code, covers pharmaceutical procurement by state and local health agencies. State and local governments buy this chemotherapy drug — a topoisomerase I inhibitor used to treat ovarian cancer, small-cell lung cancer, and cervical cancer — through pharmacy benefit programs, Medicaid procurement, corrections health services, and public hospital systems. The issuing bodies are primarily state health and human services departments, state Medicaid agencies, and public university and county hospital networks that manage formularies and drug sourcing. Work under this code includes direct manufacturer contracting for drug supply, pharmacy benefit management negotiations, volume-based pricing arrangements, and outcomes-based or value-based contracting models tied to clinical efficacy or cost containment.

The Texas Health and Human Services Commission posted a Request for Information (RFI) No. HHS0017013 on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program that would establish direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers outside traditional pharmacy benefit manager and group purchasing organization arrangements. The RFI response deadline was April 3, 2026, and the state solicited information about vendors' experience with direct contracting for self-insured employers and state health plans, flexibility to negotiate net pricing models without rebates, and capability to implement value-based agreements. This RFI represents preliminary market research to inform future formal procurement solicitations; no award value, budget, or formal evaluation criteria were specified at this stage.